开放期刊系统

黄芪甲苷治疗新生儿缺氧缺血性脑病的研究进展

段 文静, 王显 鹤*

摘要

新生儿缺氧缺血性脑病(Neonatal hypoxic-ischemic encephalopathy HIE)是有围产期窒息所致的脑损伤疾病。具有潜在
的永久性脑损伤,影响新生儿大脑发育,是新生儿神经功能障碍和死亡的最常见原因。低温性治疗作为HIE有效的治疗,
虽可发病率和死亡率,但仍有长期预后不良。基于HIE特异性治疗方案不足及预后不良表现,迫切需要寻求积极有效的
HIE治疗策略。AS-IV含有多种化合物和植物化学物质,具有抗炎、抗氧化、抗凋亡等药理活性,对神经系统具有潜在
保护作用。本综述简要探讨了AS-IV对HIE保护作用的研究机制,为HIE治疗提供新的治疗靶点,探究AS-IV对治疗新生
儿HIE潜在的治疗靶点及应用价值,以期为今后HIE治疗提供新的研究方向研。

关键词

新生儿缺氧缺血性脑病;黄芪甲苷;神经系统;抗炎;抗氧化应激;抗凋亡。

全文:

PDF

参考

[1]Luo L,Deng L,Chen Y,etal. Identification of Lipocalin 2 as a Ferroptosis-Related Key Gene Associated with Hypoxic-Ischemic

Brain Damage via STAT3/NF-κB Signaling Pathway. Antioxidants(Basel). 2023 Jan 12;12(1):186. doi:10.3390/antiox12010186.

PMID:36671050;PMCID:PMC9854551.

[2]Yang M,Wang K,Liu B,etal.. Hypoxic-Ischemic Encephalopathy:Pathogenesis and Promising Therapies. Mol Neurobiol. 2025 Feb;

62(2):2105-2122. doi:10.1007/s12035-024-04398-9. Epub 2024 Jul 29. Erratum in:Mol Neurobiol. 2025 Feb;62(2):2123.

doi:10.1007/s12035-024-04441-9. PMID:39073530.

[3]Mo Y,Zeng Y,Huo L,etal.. Early-stage effect of HIBD on neuro-motor function and organic composition of neurovascular units in

neonatal rats. Front Neurosci. 2023 Nov 21;17:1242936. doi:10.3389/fnins.2023.1242936. PMID:38075277;PMCID:PMC10702602

[4]Babbo CC,Mellet J,van Rensburg J,etal.,Coetzee M,Masemola MYK,Ballot DE,Pepper MS. Neonatal encephalopathy due to

suspected hypoxic ischemic encephalopathy:pathophysiology,current,and emerging treatments. World J Pediatr. 2024 Nov;20(11):

1105-1114. doi:10.1007/s12519-024-00836-9. Epub 2024 Sep 6. PMID:39237728;PMCID:PMC11582131.

[5]Ramirez A,Peyvandi S,Cox S,etal.. Neonatal brain injury influences structural connectivity and childhood functional outcomes. PLoS

One. 2022 Jan 5;17(1):e0262310. doi:10.1371/journal.pone.0262310. PMID:34986206;PMCID:PMC8730412.

[6]Benson JE,Bishop MR,Cohen HL. Intracranial neonatal neurosonography:An update. Ultrasound Q. 2002;18:89–114. doi:

10.1097/00013644-200206000-00003.

[7]Bano S,Chaudhary V,Garga UC. Neonatal Hypoxic-ischemic Encephalopathy:A Radiological Review. J Pediatr Neurosci. 2017

Jan-Mar;12(1):1-6. doi:10.4103/1817-1745.205646. PMID:28553370;PMCID:PMC5437770.

[8]Parmentier CEJ,de Vries LS,Groenendaal F. Magnetic Resonance Imaging in(Near-)Term Infants with Hypoxic-Ischemic

Encephalopathy. Diagnostics(Basel). 2022 Mar 6;12(3):645. doi:10.3390/diagnostics12030645. PMID:35328199;PMCID:

PMC8947468.

[9]Toorell H,Carlsson Y,Hallberg B,etal.Neuro-Specific and Immuno-Inflammatory Biomarkers in Umbilical Cord Blood in Neonatal

Hypoxic-Ischemic Encephalopathy. Neonatology. 2024;121(1):25-33. doi:10.1159/000533473. Epub 2023 Sep 29. PMID:

37778335.

[10]Bao R,Song Y,etal. BOston Neonatal Brain Injury Dataset for Hypoxic Ischemic Encephalopathy(BONBID-HIE):Part I. MRI and

Manual Lesion Annotation. bioRxiv [Preprint]. 2023 Jul 3:2023.06.30.546841. doi:10.1101/2023.06.30.546841. Update in:Sci Data.

2025 Jan 11;12(1):53. doi:10.1038/s41597-024-03986-7. PMID:37461570;PMCID:PMC10350009.

[11]Ranjan AK,Gulati A. Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy. J Clin Med. 2023 Oct 20;12

(20):6653. doi:10.3390/jcm12206653. PMID:37892791;PMCID:PMC10607511.

[12]Silveira RC,Procianoy RS. Hypothermia therapy for newborns with hypoxic ischemic encephalopathy. J Pediatr(Rio J). 2015

Nov-Dec;91(6 Suppl 1):S78-83. doi:10.1016/j.jped.2015.07.004. Epub 2015 Sep 4. PMID:26354871.

[13]Zhang J,Wu C,Gao L,etal.. Astragaloside IV derived from Astragalus membranaceus:A research review on the pharmacological

effects. Adv Pharmacol. 2020;87:89-112. doi:10.1016/bs.apha.2019.08.002. Epub 2019 Dec 18. PMID:32089240.

[14]Liang Y,Chen B,Liang D,etal. Pharmacological Effects of Astragaloside IV:A Review. Molecules. 2023 Aug 18;28(16):6118.

doi:10.3390/molecules28166118. PMID:37630371;PMCID:PMC10458270.

[15]Ren S.,Zhang H.,Mu Y.,etal.. Pharmacological effects of Astragaloside IV:a literature review. J. Tradit. Chin. Med. 2013;33

(3):413–416. doi:10.1016/s0254-6272(13)60189-2.

[16]Costa IM,Lima FOV,etal. Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models o

f Neurological Disorders:A Systematic Review. Curr Neuropharmacol. 2019;17(7):648-665. doi:10.2174/1570159X16666

180911123341. PMID:30207235;PMCID:PMC6712289.

[17]Shi G,Chen J,Zhang C,etal.Astragaloside IV promotes cerebral angiogenesis and neurological recovery after focal ischemic stroke

in mice via activating PI3K/Akt/mTOR signaling pathway. Heliyon. 2023 Nov 24;9(12):e22800. doi:10.1016/j.heliyon.2023.e22800.

PMID:38089988;PMCID:PMC10711175.

[18]Ding Y,Jie K,Xin L,etal. Astragaloside IV plays a neuroprotective role by promoting PPARγ in cerebral ischemia-reperfusion

rats. Behav Brain Res. 2025 Jan 5;476:115267. doi:10.1016/j.bbr.2024.115267. Epub 2024 Sep 26. PMID:39341463.

[19]Lin L,Zhao C,Lv H,etal.. Astragaloside IV promotes neuronal axon regeneration by inhibiting the PTEN/AKT pathway. Brain Res.

2025 Mar 1;1850:149451. doi:10.1016/j.brainres.2025.149451. Epub 2025 Jan 8. PMID:39793915.

[20]Li M,Li H,Fang F,etal.. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion

in mice via anti-inflammatory mechanisms. Neurosci Lett. 2017 Feb 3;639:114-119. doi:10.1016/j.neulet.2016.12.046. Epub 2016

Dec 21. PMID:28011393.

[21]Zhang C,Shi Z,Xu Q,etal.. Astragaloside IV alleviates stroke-triggered early brain injury by modulating neuroinflammation and

ferroptosis via the Nrf2/HO-1 signaling pathway. Acta Cir Bras. 2023 Mar 24;38:e380723. doi:10.1590/acb380723. PMID:36995819;

PMCID:PMC10041803.

[22]He L,Sun J,Miao Z,etal. Astragaloside IV attenuates neuroinflammation and ameliorates cognitive impairment in Alzheimer's

disease via inhibiting NF-κB signaling pathway. Heliyon. 2023 Feb 3;9(2):e13411. doi:10.1016/j.heliyon.2023.e13411. PMID:

36820018;PMCID:PMC9937980.

[23]Rodrigo J,Fernández AP,Serrano J,etal.. The role of free radicals in cerebral hypoxia and ischemia. Free Radic Biol Med. 2005;

39:26–50. doi:10.1016/j.freeradbiomed.2005.02.010.

[24]Huang XP,Qiu YY,Wang B,etal. Effects of Astragaloside IV combined with the active components of Panax notoginseng on

oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral

ischemia-reperfusion in mice. Pharmacogn Mag. 2014 Oct;10(40):402-9. doi:10.4103/0973-1296.141765. PMID:25422538;

PMCID:PMC4239715.

[25]Meng Y,Yu S,Zhao F,etal. Astragaloside IV Alleviates Brain Injury Induced by Hypoxia via the Calpain-1 Signaling Pathway.

Neural Plast. 2022 Dec 3;2022:6509981. doi:10.1155/2022/6509981. PMID:36510594;PMCID:PMC9741538.

[26]Sun Q.,Jia N.,Wang W.,etal.Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the

mitochondrial permeability transition pore opening. PLoS One 9:e98866. 10.1371/journal.pone.0098866

[27]Lin Y,Cheng W,Chang J,etal. Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in

Spinocerebellar Ataxia Type 3. Sci Rep. 2024 Oct 29;14(1):25979. doi:10.1038/s41598-024-77763-2. PMID:39472629;PMCID:

PMC11522510.

[28]Xu Z,Yang D,Huang X,etal.. Astragaloside IV Protects 6-Hydroxydopamine-Induced SH-SY5Y Cell Model of Parkinson's

Disease via Activating the JAK2/STAT3 Pathway. Front Neurosci. 2021 Mar 23;15:631501. doi:10.3389/fnins.2021.631501. PMID:

33833662;PMCID:PMC8021720.

[29]Shao A,Guo S,Tu S,etal.. Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats. Int

J Med Sci. 2014 Aug 8;11(10):1073-81. doi:10.7150/ijms.9282. PMID:25136262;PMCID:PMC4135229.

[30]Zhang ZG,Wu L,Wang JL,etal.. Astragaloside IV prevents MPP+-induced SH-SY5Y cell death via the inhibition of Bax-mediated

pathways and ROS production. Mol Cell Biochem. 2012;364:209–216. doi:10.1007/s11010-011-1219-1.

[31]Hou B,Liu R,Wu Y,etal.. Astragaloside IV Reduces Cerebral Ischemia/Reperfusion-Induced Blood-Brain Barrier Permeability in

Rats by Inhibiting ER Stress-Mediated Apoptosis. Evid Based Complement Alternat Med. 2020 Oct 26;2020:9087873. doi:

10.1155/2020/9087873. PMID:33193803;PMCID:PMC7641265.

[32]Wu H,Chen S,You G,etal.. The Mechanism of Astragaloside IV in NOD-like Receptor Family Pyrin Domain Containing 3

Inflammasome-mediated Pyroptosis after Intracerebral Hemorrhage. Curr Neurovasc Res. 2024 ; 21 ( 1 ): 74-85. doi :

10.2174/0115672026295640240212095049. PMID:38409729.

[33]Ben Y,Hao J,Zhang Z,etal.. Astragaloside IV Inhibits Mitochondrial-Dependent Apoptosis of the Dorsal Root Ganglion in Diabetic

Peripheral Neuropathy Rats Through Modulation of the SIRT1/p53 Signaling Pathway. Diabetes Metab Syndr Obes. 2021 Apr 14;14:

1647-1661. doi:10.2147/DMSO.S301068. PMID:33883914;PMCID:PMC8055373.

[34]Sun J,Chen XL,Zheng JY,etal.. Astragaloside IV protects new born rats from anesthesia-induced apoptosis in the developing brain.

Exp Ther Med. 2016 Sep;12(3):1829-1835. doi:10.3892/etm.2016.3519. Epub 2016 Jul 13. PMID:27588101;PMCID:

PMC4998115.

[35]Chen TB,Zhou HS,Xiong LL. Single cell sequencing technology and its application in Hypoxic ischemic encephalopathy research.

Ibrain. 2021 Sep 28;7(3):227-234. doi:10.1002/j.2769-2795.2021.tb00086.x. PMID:37786794;PMCID:PMC10528982.

[36]Pedroza-Garcia KA,Calderon-Vallejo D,Quintanar JL. Neonatal hypoxic-ischemic encephalopathy:perspectives of neuroprotective

and neuroregenerative treatments. Neuropediatrics. 2022;53:402–17

[37]Inder TE,Volpe JJ. Chapter 20 - Hypoxic-Ischemic Injury in the Term Infant:Clinical-Neurological Features,Diagnosis,

Imaging,Prognosis,Therapy. In:Volpe" ["Joseph J.,Inder" "Terrie E.,Darras" "Basil T.,Vries" "Linda S. de,Plessis" "Adré J.

du,Neil" "Jeffrey J.,et al.,editors. Elsevier;2018. p. 510–563.e15.

[38]Chan NH,Hawkins CC,Rodrigues BV,etal.. Neuroprotection for neonatal hypoxic-ischemic encephalopathy:A review of novel

therapies evaluated in clinical studies. Dev Med Child Neurol. 2024 Nov 20. doi:10.1111/dmcn.16184. Epub ahead of print. PMID:

39563426.

[39]Gonzalez FF. Neuroprotection Strategies for Term Encephalopathy. Semin Pediatr Neurol. 2019;32:100773.

[40]孙丽,王岭,李艳,等. 黄芪甲苷对大鼠脑缺血再灌注损伤的保 护作用和机制研究[J]. 中国临床神经科学,2014,22

(1):43- 45.

[41]刘春辉,汪立刚,王战云.黄芪甲苷对 HIBD 大鼠脑组织保护作用的研究[J].哈尔滨医科大学学报,2019,53(01):28-30+34.

[42]李娜.黄芪甲苷调控 MMP-9 介导 NLRP3/Caspase-1 信号通路改善缺氧缺血性脑损伤的分子机制[D].辽宁中医药大学,

2021.DOI:10.27213/d.cnki.glnzc.2021.000042.


(1 摘要 Views, 1 PDF Downloads)

Refbacks

  • 当前没有refback。